COMPANY
Clinical Phase 2
Keywords: metabolic type 2 diabetes mellitus obesity GLY-200
Location: Baltimore, MD · source · Oct 15, 2026
Profile checked Oct 10, 2026
Timeline
- Trial start Phase 2: A 16-Week Study to Evaluate the Efficacy, Safety, and Tolerability of GLY-200 in Participants With Obesity source ↗
- Trial start Phase 2: A Study Evaluating the Safety, Tolerability, and Pharmacodynamic Effects of GLY-200 in Type 2 Diabetic Patients source ↗
Clinical trials (lead sponsor) 2
| Record | Title | Phase | Status | Start | Primary completion |
|---|
| NCT05478525 | A Study Evaluating the Safety, Tolerability, and Pharmacodynamic Effects of GLY-200 in Type 2 Diabetic Patients | Phase 2 | Completed | Aug 3, 2022 | Mar 14, 2023 (actual) |
| NCT06259981 | A 16-Week Study to Evaluate the Efficacy, Safety, and Tolerability of GLY-200 in Participants With Obesity | Phase 2 | Completed | May 20, 2024 | Oct 23, 2024 (actual) |
